ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0811

Using a Smartphone App to Detect and Characterise Real-Time Patient-Reported Flares in Rheumatoid Arthritis

Julie Gandrup, Sabine N van der Veer, John McBeth and Will Dixon, University of Manchester, Manchester, United Kingdom

Meeting: ACR Convergence 2021

Keywords: Epidemiology, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA (0786–0812)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Flares are an intrinsic part of the rheumatoid arthritis (RA) disease course and may impact clinical and patient outcomes. Severity, frequency and duration of flares matter, but the clinical assessment is limited by patient recall. Consumer technologies make it possible to capture and explore patient-reported flares in near real time. We used smartphone app data to explore the frequency of patient-reported flare weeks and their associations with various summary features of daily symptoms reported during the preceding week.

Methods: The Remote Monitoring of Rheumatoid Arthritis (REMORA) study aimed to improve monitoring of disease severity in RA. Patients tracked daily symptoms on a 0-10 scale (pain, fatigue, function, sleep, coping, physical and emotional wellbeing) and weekly flares on the REMORA smartphone app.

A flare week was defined as the seven days leading up to the weekly flare-question “Have you experienced a flare in the last week?” where the patient answered “yes” (Fig. 1). We summarised the number of patient-reported flare weeks. Symptom scores in flare and non-flare weeks were compared.

For each week prior to a flare question, we calculated the following summary features for all daily symptoms: 1) mean score, 2) standard deviation (SD), and 3) slope (Fig. 1, inset). Mixed effects logistic regression models quantified the associations between flare weeks and each summary feature.

Results: Twenty patients tracked symptoms over three months. 60% were female, all but one were white British, and mean age was 56.9±11.1 years. The median number of days in the study was 81 (interquartile range (IQR) 80, 82). We included 168 participant weeks. In total, 15/20 participants reported at least one flare week, with 54 patient-reported flare weeks in total. Participants reported a median of two flare weeks (IQR 0.75, 3.5).

In paired analyses, all mean symptom scores were significantly higher (difference on average 0.67 (SD 0.22)) in flare weeks compared to non-flare weeks except for sleep (p< 0.05). The SDs, a measure of variability, were slightly higher in flare weeks, but only significantly different from non-flare weeks for emotional wellbeing. For slope, there was an increase for all symptoms in flare weeks, although only the slopes of pain, physical wellbeing, and coping were statistically significant.

Due to strong correlations between symptoms, multivariate modelling of all symptoms and their summary features was not possible. Rather, we modelled pain as an example using each of its three derived features. In the full pain model, mean pain scores appeared to be more clearly associated with a flare (odds ratio 1.83 (1.15; 2.97)) than the change in scores in the preceding week.

Conclusion: In our RA cohort, self-reported flares were frequent. Flare weeks were broadly associated with higher scores (for mean, variability, and slope) across a range of daily symptoms in the preceding week, but the absolute value seemed more important than the change. The correlation between daily symptoms made it impossible to disentangle the contribution of individual symptoms to the flare experience.

Future analysis of daily symptoms may allow us to predict imminent flares, opening the opportunity for just-in-time interventions.

Figure 1: Example patient illustrating daily and weekly symptom tracking. The red circles indicate that the patient answered “yes” to the weekly flare question, the white circles when the patient answered “no”. The seven days leading up to the flare question are marked with grey boxes to illustrate flare (darker) and non-flare (lighter) weeks. In the inset, the three summary features are highlighted for pain: 1) Mean, 2) Standard deviation, and 3) Slope.


Disclosures: J. Gandrup, None; S. van der Veer, None; J. McBeth, None; W. Dixon, Google, 2, Bayer, 2, Abbvie, 2.

To cite this abstract in AMA style:

Gandrup J, van der Veer S, McBeth J, Dixon W. Using a Smartphone App to Detect and Characterise Real-Time Patient-Reported Flares in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/using-a-smartphone-app-to-detect-and-characterise-real-time-patient-reported-flares-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/using-a-smartphone-app-to-detect-and-characterise-real-time-patient-reported-flares-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology